Povidone-Iodine as an Adjuvant Therapy for Refractory Gonorrhea Keratoconjunctivitis: A Case Report
Gonorrhea keratoconjunctivitis is a sight-threatening condition that requires hospitalization and systemic antibiotic therapy. We report a case of a 47-year-old man suffering from gonococcal conjunctivitis with progressive corneal involvement despite three days of appropriate topical and intravenous antibacterial therapy. The patient received adjuvant treatment with 5% topical povidone-iodine, which had an immediate beneficial effect. One day after the application, the patient showed a resolution of severe exudative discharge with improvement in epithelial defects and thinning. By hospital day seven, the corneal defect and thinning had both resolved. Povidone-iodine may be a low-cost, safe, and potentially effective adjuvant therapy for refractory gonococcal keratoconjunctivitis in adult individuals unresponsive to standard-of-care antibiotic therapy after 72 hours of treatment. However, there is no evidence to support povidone-iodine as a standalone treatment for gonococcal conjunctivitis. Further research with a greater number of patients is needed to determine its true utility.
Authors
- Stephen LoBue (ORCID: https://orcid.org/0000-0003-2899-7730)
- Tim Brandenburg (ORCID: https://orcid.org/0000-0003-2904-4341)
- Ayorinde Cooley (ORCID: https://orcid.org/0000-0002-8710-6910)
- Sinan Albear
- Jennifer Park (ORCID: https://orcid.org/0000-0002-1269-739X)
- Rebecca Friedes
Institutions
- SUNY Downstate Health Sciences University (US)
- Willis-Knighton Cancer Center (US)
Publication Details
- Journal
- Cureus
- Published
- 2025-05-07
- DOI
- https://doi.org/10.7759/cureus.83676
- Primary Topic
- Reproductive tract infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00